Myriad Genetics pays former CCO Brian Donnelly $1.32M severance; accelerates 2 years of equity vesting
MYRIAD GENETICS INC
Brian Donnelly, former Chief Commercial Officer, separated Sept 21, 2026; departure from CCO role effective Sept 16, 2026.
Lump-sum severance of $1,322,294 equals base salary $576,800, target bonus $432,600, and pro-rata FY2026 bonus $312,894.
Time-based equity awards scheduled to vest within 2 years of separation accelerate, deemed monthly over 24 months; performance awards remain outstanding up to 2 years.
COBRA premiums paid up to 1 year or until new employment; agreement dated Oct 6, 2026, effective Oct 14, 2026 after 7-day revocation.
On October 6, 2026, Myriad Genetics, Inc. (the “Company”) entered into a Separation Agreement and Release of Claims (the “Separation Agreement”) with Brian Donnelly, the Company’s former Chief Commercial Officer. As previously disclosed, Mr. Donnelly departed from his position as Chief Commercial Officer of the Company, effective September 16, 2026.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Brian Donnelly departed as Chief Commercial Officer at MYRIAD GENETICS INC.
Action
departed
Role
Chief Commercial Officer
Exact text from the filing
On October 6, 2026, Myriad Genetics, Inc. (the “Company”) entered into a Separation Agreement and Release of Claims (the “Separation Agreement”) with Brian Donnelly, the Company’s former Chief Commercial Officer. As previously disclosed, Mr. Donnelly departed from his position as Chief Commercial Officer of the Company, effective September 16, 2026.
This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.